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Abstract
Background: Spinal cord injury is a serious and debilitating condition, affecting millions of people worldwide.
Long seen as a permanent injury, recent advances in stem cell research have brought closer the possibility of
repairing the spinal cord. One such approach involves injecting oligodendrocyte progenitor cells, derived from
human embryonic stem cells, into the injured spinal cord in the hope that they will initiate repair. A phase I clinical
trial of this therapy was started in mid 2010 and is currently underway.
Discussion: The theory underlying this approach is that these myelinating progenitors will phenotypically replace
myelin lost during injury whilst helping to promote a repair environment in the lesion. However, the importance of
demyelination in the pathogenesis of human spinal cord injury is a contentious issue and a body of literature
suggests that it is only a minor factor in the overall injury process.
Summary: This review examines the validity of the theory underpinning the on-going clinical trial as well as
analysing published data from animal models and finally discussing issues surrounding safety and purity in order to
assess the potential of this approach to successfully treat acute human spinal cord injury.
Background
Clinicians currently have very limited treatment options
when managing a patient with spinal cord injury (SCI).
Symptom control, supportive care and rehabilitation are
the mainstays of treatment [1] and a reversal of the injury
process has, until recently, been science fiction. However,
developments in the field of stem cells have led many to
believe that regeneration of an injured spinal cord is
indeed possible and one such approach is currently
undergoing a phase I clinical trial [2]. In the first trial of
its kind, oligodendrocyte progenitor cells (OPCs) derived
from human embryonic stem cells (hESCs) will be
injected into the spinal cords of patients with an acute
thoracic SCI to assess safety and efficacy in restoring
neurological function [3]. Initially hailed as a major
advancement [4] and treated with optimism in the popu-
lar press [5], this trial has already experienced setbacks
and was placed on clinical hold by the FDA in 2009 due
to safety issues [6]. Whilst the trial has now been given
permission to proceed [7], lessons learnt from French
gene therapy trials in 2003, in which retroviral gene
insertion triggered leukaemia in some patients, show that
any failures can potentially set back an entire field [8]. If
similar serious issues of safety or efficacy arise, the effect




SCI, caused by accidental injury in most cases [9], has
universal importance but is particularly relevant to young
people, with the average injury age 33 years [9]. A
moment of trauma sets in motion a disease process ulti-
mately resulting in partial or full paralysis and loss of
some or all sensory input below the injury level, clinically
known as incomplete or complete injury respectively
[10]. With no cure currently available, patients can
expect to spend the rest of their life in a wheelchair and
approximately 16% of patients (those with complete tet-
raplegia [11]) face the prospect of life-long full paralysis
from the neck down. In addition, many of the millions of
* Correspondence: robert.watson@gtc.ox.ac.uk
1Green Templeton College, Woodstock Road, Oxford, OX2 6HG, UK
Full list of author information is available at the end of the article
Watson and Yeung BMC Neurology 2011, 11:113
http://www.biomedcentral.com/1471-2377/11/113
© 2011 Watson and Yeung; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.patients worldwide also experience incontinence [12],
chronic pain [13] and psychiatric disorders [14,15]. This
has an important social toll as many patients who have
suffered an SCI experience significant disruption to their
social and work lives, having a profound impact on their
family and society around them [16]. Further, the direct
costs of caring for patients with an SCI are enormous
and are estimated to be in the region of $7 billion per
annum in the US [17].
Primary and secondary disease
The pathophysiology of SCI is biphasic, comprising a pri-
mary and secondary injury phase [18]. The primary injury
phase refers to the injury itself, consisting of mechanical
disruption of tissue caused by the force imparted by the
primary injury mechanism. Although every human injury
is unique, the most common injury mechanism is contu-
sion (analogous to soft tissue bruising), often with pro-
longed compression due to crushing of the vertebrae
[19]. Hyper-bending, hyper-stretching, rotation and
laceration can also occur [10], although complete trans-
ections of the cord are rare and usually intact white mat-
ter is seen to traverse the lesion [20,21]. Whilst tissue
damage can occur during this immediate phase, there is
a surprising paucity of permanent pathological changes,
underscoring the importance of secondary injury
mechanisms [22].
The secondary injury phase depends on the time post
injury and the processes occurring (summarised in Figure
1). Most damage and cellular loss occurs during the acute
and intermediate phases where an extensive range of pro-
cesses result in widespread apoptosis and necrosis of both
neurons and oligodendrocytes, leading to neurological def-
icits [22-24]. The late intermediate and chronic phases are
characterised by progressive degeneration, accompanied
by attempts at endogenous repair [19]. Morphological
changes associated with the chronic phase (Figure 1) are
significant barriers to any cell replacement therapy and
hence the clinical protocol for the use of OPCs involves
administration during the intermediate phase, 7-14 days
post injury [25,26].
Stem cell therapies and SCI
It is possible to classify ‘stem cells’ into two broad cate-
gories, embryonic and somatic; the latter term including
all stem cells present in the adult as well as those found
in foetal and neonatal tissues [27]. Embryonic stem cells
are derived from the human blastocyst and maintain the
ability to differentiate into any cell type (pluripotency)
[28], whilst somatic stem cells are able to differentiate
into a limited number of cell lineages (multipotency). It
is this ability to differentiate into a variety of cell types, as
well as secrete growth factors, that has gained interest
from the field of spinal cord injury. It is hoped that stem
cells can be used to replace neural cells lost during the
injury process and stimulate a repair environment [29].
A number of stem cell types including mesenchymal
stem cells, olfactory ensheathing cells and neural stem
cells have been considered for use in SCI. However,
further discussion of the use of these cell types is outside
the scope of this article and is well reviewed elsewhere
[27,29-33].
The cell type currently being trialled in human patients,
and the focus of this article, is the oligodendrocyte pro-
genitor cell. These cells are derived from human embryo-
nic stem cells by culturing them in conditions to drive
commitment to an oligodendroglial lineage [34,35]. Once
purified, up to 95% of these cells display markers charac-
teristic of oligodendroglial cells - GalC, RIP and O4 - and
morphologically resemble oligodendroglial cells [26].
These progenitors can then be injected into the spinal
cord where, in a demyelinating environment, they further
differentiate into oligodendrocytes - the myelinating cells
of the central nervous system [26]. In the human SCI
lesion site, it is hoped that OPCs will work as a “combi-
nation therapy” [29] - phenotypically replacing lost oligo-
dendrocytes and hence remyelinating axons that have
become demyelinated during SCI, as well as secreting
neurotrophic factors to establish a repair environment in
the lesion [29].
This review sets out to assess the potential of this treat-
ment to successfully heal SCI by first looking at the role
of demyelination in the pathogenesis of SCI. We then
assess the importance of trophic support and the repair
environment before analysing in vivo models of OPC
treatment. Finally, practical, safety and ethical issues will
be discussed.
Discussion
The role of demyelination and axonal sparing in SCI
O n eo ft h ek e yp r e m i s e so fu s i n gO P Ct r a n s p l a n t sf o r
treatment of SCI is that demyelination is a major contribu-
tor to the pathogenesis of the injury. Clearly, in order for
remyelinating therapies to succeed there must be appro-
priate targets - i.e. naked, intact axons - in which function
is restored to some degree following treatment. Somewhat
surprisingly, the existence of such targets following human
SCI is controversial and casts doubt on much of the fun-
damental science underlying OPC treatment. Whilst a
number of animal studies [36,37] have demonstrated mye-
lin loss with sparing of the associated axon - so-called ‘pri-
mary demyelination’ - the extent to which this occurs
following human injury is ambiguous and a number of
post mortem studies of human SCI have suggested that it
may not occur to a significant degree [20,22,38].
I tm a yb ep o s s i b l et oe x p l a i nt h eo b s e r v e dd i f f e r e n c e
in the extent of primary demyelination between post
mortem human samples and animal models. Experimen-
tal data demonstrates that axons need myelin for trophic
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PLP and DM-20, typically show axonal swelling and
degeneration [39]. Therefore any naked axons in
humans may degenerate if they are not provided with
support from oligodendrocytes and hence wouldn’tb e
detected post mortem. Additional mouse data has sup-
ported this theory by showing a close correlation
between myelin status and axonal survival [40].
Nonetheless, there are a number of inconsistencies
with this explanation. Firstly, investigations in rats have
identified chronically demyelinated axons [37], suggest-
ing that some axons are capable of surviving without
oligodendrocyte support. Additionally, were this expla-
nation valid, then one would expect to see naked axons
in acute or intermediate stage post mortem lesions,
before they had time to degenerate. However, this is not
reported to be the case [20,22,38].
In summary, the role of demyelination is far from clear.
Whilst some animal studies [36,37] suggest that naked,
primary demyelinated axons - the target for OPC treat-
ment - exist, post mortem human studies do not corrobo-
rate this [20,22,38]. This disparity could be due to the
explanation given above, however, as discussed, this has a
number of caveats. Nonetheless there could be other rea-
sons for the conflicting results between human and animal
s t u d i e ss u c ha st h ef a c tt h a tpost mortem samples - particu-
larly from acute or intermediate phase lesions - necessarily
come from injuries associated with high mortality and
h e n c er e p r e s e n tam o r es e v e r el e s i o n .A ss u g g e s t e db y
Guest et al (2005), primary demyelination is more likely in
less severe injury where axons can survive but oligodendro-
cytes cannot [38]. Perhaps, as suggested by Rowland et al,
emerging magnetic resonance imaging technologies such
as magnetization transfer and diffusion tensor imaging
which allow the structural integrity of tissue to be imaged
in live patients will clarify the situation in humans [19].
Overall, despite the prominent role for demyelination
suggested in animal studies, a lack of consensus on the
Figure 1 The key events following SCI. Adapted from [19-22]. BBB: Blood Brain Barrier; ROS: Reactive Oxygen Species.
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tainty regarding how successfully OPCs can treat human
SCI. Indeed, even if remyelination is a successful strat-
egy, there are many barriers to clinical improvement.
For example, glial scar formation can create a physical
barrier to OPCs whilst a number of molecules can have
an inhibitory effect on OPCs. For example, both chon-
droitin sulphate proteoglycans (CSPGs) and TNF-a
found within the scar have been shown to reduce OPC
growth [41,42], whilst other studies have shown that
bone morphogenic protein (BMP) produced by astro-
cytes can reduce OPC differentiation into oligodendro-
cytes and promote differentiation into astroctyes [43].
Trophic support and the importance of a repair
environment
OPC transplantation is a dual strategy, aiming not just to
allow remyelination but also providing trophic support
and a repair environment [44]. Spinal cord injury sets in
motion a plethora of repair mechanisms, including endo-
genous remyelination and increased expression of a num-
ber of neurotrophic factors such as transforming growth
factor-b2( T G F - b2) and brain-derived neurotrophic
factor (BDNF) [45,46]. Such up-regulation is thought to
contribute to neuroprotection and even axonal sprouting
[47]. However, axonal sprouting and endogenous repair
is often abortive - due, in part, to an insufficient repair
environment to overcome inhibitory mechanisms or pro-
mote maintained regeneration [48]. Moreover, although
endogenous remyelination is often seen following SCI, it
is usually functionally and anatomically incomplete
[48-50]. It is therefore hoped that the grafting of a large
number of OPCs soon after injury will create a ‘repair
environment’ and allow these processes to develop
further.
A host of evidence is weighing up in favour of this the-
ory - OPCs are capable of producing numerous neurotro-
phins including midkine, TGF-b2 and BDNF, contributing
to a repair environment [51] and even promoting neurite
outgrowth of rat sensory neurons in vitro [51]. In vivo stu-
dies (discussed in more detail below) have also suggested
that OPC transplantation can significantly alter lesion
pathogenesis and influence gene expression towards an
uninjured pattern [52]. Indeed, in one experimental sys-
tem, exposure of media conditioned by OPCs and oligo-
dendrocytes alone was enough to increase the survival and
axonal lengthening of neurons [53]. Therefore it is possi-
ble that even in the absence of remyelination, OPC trans-
plantation may bring clinical improvement by providing
trophic support and creating a regenerative environment,
preventing the cellular damage and apoptosis seen in the
secondary injury phase.
Despite this, eliciting neural regrowth is an ambitious
goal as despite early optimism, neurotrophin based
therapies, which aim to induce a repair environment,
have been largely unsuccessful [54-56] and harnessing
this process has remained elusive. Moreover, sprouting
can also be pathogenic as new connections made by
sensory afferents can lead to neuropathic pain [57] and
autonomic dysreflexia [58]. Further, the inflammatory
milieu following SCI is extremely complex and so the
timing of any acute graft needs to be extremely carefully
considered [59]. Hence whilst attempting to provide a
supportive environment is a reasonable approach, it may
be difficult to achieve in practice.
In summary, the potential benefit of remyelination
remains controversial due to disagreements in the role
of this process in human SCI. In addition, even if a
remyelinating strategy is the correct one, there are a
number barriers to success remaining including scar for-
mation, inhibitory molecules and the complexity of the
inflamed lesion. The latter also makes generation of a
repair environment somewhat complex. These factors
l e a v ec h a l l e n g e st ob eo v e r c o m ei nt h ed e v e l o p m e n to f
this therapy.
In vivo evidence for potential of OPC transplantation
Despite much debate surrounding the underlying princi-
ples of the potential of OPC transplants, a number of
whole body in vivo experiments have been conducted to
assess OPC-based therapy. The most important of these
in the public domain, cited on the announcement of the
clinical trial [4], is that of Keirstead et al (2005) [44]. The
authors successfully demonstrated that injection of OPCs
into rats with a thoracic contusion SCI seven days post-
injury led to remyelination and restoration of some loco-
motor function. A similar study into cervical SCI [52],
conducted by the same group, obtained similar results -
demonstrating that OPC transplantation can improve
forelimb motor function as well as altering lesion patho-
genesis; shown by increased white and grey matter spar-
ing, decreased cavitation and altered gene expression
[52]. This, too, was claimed to be “proof-of-concept” for
the OPC clinical trials in a separate press release [60].
Subsequently, other groups have also shown neurological
improvements following OPC injection into rodent mod-
els of SCI, further validating this approach [61-63].
Whilst these papers [44,52] undoubtedly offer strong evi-
dence for the promise of OPC therapy, there are a num-
ber of considerations to be made before these results can
be applied to human therapy.
Firstly, contusion injury was produced by an ‘impactor’ -
a device which transiently delivers a specific force to the
posterior of the spinal cord [64]. It is questionable how
accurately this models human SCI where a variety of
injury mechanisms often occur anteriorly [65], followed by
prolonged compression, spinal fractures [66], haemorrhage
and inflammation [67] and serious systemic injuries.
Watson and Yeung BMC Neurology 2011, 11:113
http://www.biomedcentral.com/1471-2377/11/113
Page 4 of 9Secondly, all SCIs were elicited under anaesthesia, fol-
lowed by sterile wound closure and antibiotics [44,52].
Anaesthesia is known to have neuroprotective properties
[68,69], and may therefore alter the injury outcome, whilst
antibiotics prevent infection, a factor that can exacerbate
human SCI [9]. Thirdly, all animals were surgically pre-
pared before injury - the paravertebral muscles were dis-
sected and the spinal laminae removed. This procedure is
known to reduce secondary disease processes such as
swelling and oedema, altering disease pathogenesis [70].
Furthermore, these studies used locomotor function as a
guide for neurological improvement but made no attempt
to examine sensory or autonomic function - something
that any treatment of SCI needs to address. Additionally,
in the 2005 study, locomotion was assessed, in part, using
the Basso Beattie and Bresnahan (BBB) scale [44], the sen-
sitivity and reproducibility of which has been criticised
[71]. Finally it is of interest to note that the authors of the
2005 study declare “no potential conflict of interest” [52]
despite their work being funded by the company running
the clinical trial, and being named by the latter as ‘colla-
borators’ [60]. This is probably of no consequence, but
increased transparency would likely bestow greater confi-
dence in the results obtained.
Whilst it is possible to criticise the extrapolation of ani-
mal data to humans, particularly in the context of SCI
[72], one must bear in mind that whilst small-animal mod-
els may be flawed, they are still an important tool and live
in vivo experiments are a crucial element of preclinical
investigation. In spite of the aforementioned conflict of
interest, the studies were rigorously conducted with
appropriate controls and blinding of investigators where
necessary. The fact that significant positive results were
obtained, for both thoracic and cervical injury, provides a
reasonable basis for development of this treatment. Whilst
historically, promising animal data has often translated
poorly into clinical success [72], it remains to be seen
whether this will be true in this case.
Practical issues
Safety and purity
Transplanting pluripotent cells derived from embryos
into adult humans clearly has associated risks. Two
major possible adverse effects are teratoma formation
and allogeneic rejection but a number of other complica-
tions could also potentially arise. Issues surrounding the
safety and purity of the OPCs need to be carefully con-
sidered, as they could be a major barrier to the success of
this therapy.
Teratoma formation
Human embryonic stem cells (hESCs) share a number
of phenotypes with tumour cells - for example a rapid
replication rate, genetic instability and telomerase activ-
ity [73]. On injection into immunodeficient mice, hESCs
inevitably form teratomas (benign tumours comprising
of tissue from all three embryonic layers) and indeed
this association is so strong that this has become a test
of pluripotency [73]. To mitigate the risk of teratoma
formation, it is possible to employ one of three strate-
gies: differentiation of pluripotent stem cells, manipula-
tion of genetics to prevent tumorigenesis or careful
surveillance and removal of any tumours that form in
the patient [74].
Therapies involving OPCs are applying the first of these
strategies by pre-differentiating hESCs into progenitor
cells, abrogating the risk of teratoma formation [26].
Throughout intensive preclinical screening no evidence of
aberrant growth or teratomas was found [75], implying
that this strategy was successful. However, the risk of
tumour formation a number of years after grafting, or due
to contamination with undifferentiated hESCs, cannot be
eliminated, especially as it is extremely difficult to obtain
OPCs with 100% purity [34,44]. New culture techniques
may improve purity (discussed below) but the risk of con-
tamination remains valid. Indeed, during animal studies,
non-neural tissue and cysts were found in some cases
(Figure 2) and the current trial was placed on clinical hold
for over a year pending further investigation by the FDA
[6]. Whilst the trial has now resumed, it is not possible to
predict the long-term consequences and risks at this stage.
Immunogenicity and xenogenic culture
Studies evaluating the immunogenicity of OPCs indicate
that they elicit only a mild immune response [76], perhaps
a product of the low immunogenicity of hESCs [77,78],
although some authors have suggested that this may not
always be the case [79]. Either way, OPCs are an allogeneic
transplant and as such pose a risk of immune rejection
and subsequent exacerbation of any lesion. For this reason,
the trial protocol includes low-dose immunosuppression
Figure 2 Conclusions from non-clinical safety studies of the
OPCs to be injected into human spinal cords. Adapted from [25].
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have a number of side effects and in fact the first patient
in the current phase I trial experienced a “mild” adverse
event relating to tacrolimus (Figure 3).
T h ep r o p e n s i t yt oc a u s ei m m u n er e j e c t i o no rt u m o u r
formation is increased if the sample of cells grafted is
impure. Many differentiation protocols, including the
one used for the on-going trial [80], still use xenogenic
products which can lead to alterations in cell surface
molecules and carries a risk of pathogen cross-transfer.
Recent advances have led to the emergence of xeno-free
culturing protocols [81] which may facilitate the deriva-
tion of purer samples of donor cells and hence may
help to mitigate the chance of adverse events.
Overall, risk analysis and preclinical testing for OPCs
has been thorough and many other potential side effects
such as allodynia or adverse effects on locomotion have
been extensively screened for (Figure 2) and found to be
of minimal risk [25,82]. However, it is not possible to ever
eliminate the risk of adverse events and due to the variety
and capriciousness of side effects, combined with cautious
regulation, safety concerns could prove a serious hin-
drance to OPC treatment.
Commercial viability
OPCs are commercially viable due to the fact that they are
durable, capable of tolerating freeze-thaw cycles and
immortal [29]. This makes laboratory handling straightfor-
ward and standardisation and scaling up of manufacturing
possible. Commercial viability is a very important factor
for bringing new treatments to the clinic and the fact that
OPCs fulfil these criteria enhances their potential to suc-
ceed. However, were OPCs to suffer a major setback dur-
ing their first trial, investments - currently sustaining the
on-going trial - may start to wane, thus jeopardising any
future potential success.
Ethical issues
Due to complex ethical issues [83], there is a corpus of
opposition to hESC research and associated therapies
[84]. These ethical dilemmas are diverse, but in summary,
opposition tends to focus on the fact that research using
human embryos violates the sanctity of life, with neces-
sary destruction of these embryos tantamount to killing a
human and hence morally unjustifiable [85]. Proponents
of hESC research would counter that the moral status of
a blastocyst is ambiguous and that whilst destruction of
an embryo is undesirable, it is vindicated by the benefits
it brings [85]. Furthermore, many embryos are ‘spares’
from IVF clinics, destined for destruction [85]. This is a
simplistic overview, but regardless of any debate, opposi-
tion to this work is likely to always remain. Although pri-
vate corporations will probably always be able to
continue with hESC research, especially in an interna-
tional context, any failures in this field would do little to
quell opposition, potentially slowing future progress.
Recently, ethical concerns have also been raised regard-
ing the on-going clinical trial. In particular, Bretzner et al
(2011) raised objections to the design and patient popula-
tion [86]. They claim that patients diagnosed with an
a c u t eS C Im a yb ee s p e c i a l l yv u l n e r a b l et o“therapeutic
misconception”, whereby they believe and are motivated
by the idea that they will gain therapeutic benefit from
the trial [86]. Further, they suggest that enrolling patients
in the acute phase risks jeopardizing any spontaneous
recovery and that there are more appropriate patient
populations for a phase I safety trial of OPCs [86]. Whilst
those responsible for the trial have strongly defended the
chosen protocol [87] and other commentators have
recently written critiques of Bretzner et al’s article [88], it
is clear that this pioneering study is, and will continue to
be, subject to intense scrutiny and opposition. This pres-
sure is likely to augment the consequences of any success
or failure.
Progress of the clinical trial
The on-going phase I clinical trial into the use of OPCs
for spinal cord injury has now been in progress for 9
months. Two patients have so-far undergone treatment
and updates on the trial have recently been given at con-
ferences in the first half of 2011 [89]. The trial is continu-
ing to recruit patients [89]. The investigators state that
“no serious safety issues have occurred to date” [90] and
whilst no conclusions can be drawn until the trial has
reached completion and the data appropriately collected
and analysed, it is promising that there have been no
major setbacks since its commencement (Figure 3) [91].
It should also be noted, however, that as this is a phase I
clinical trial, the primary outcome is safety. Hence it will
not be until the completion of phase II and III efficacy
trials that inferences about the effectiveness of this ther-
apy can be confidently drawn.
Summary
This review set out to assess the potential of OPCs to
treat SCI by examining injury pathogenesis, current data
Figure 3 Outcomes reported in June 2011 of the phase I
clinical trial of OPCs in human lesions. Adapted from [91]
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tions. The situation surrounding pathogenesis is unclear,
with opinion regarding ther o l eo fd e m y e l i n a t i o ni n
human injury divided. Animal data - albeit from
researchers keen to develop new technologies - suggests
an important role for demyelination whilst clinical sam-
ples, notwithstanding their own caveats, indicate the con-
trary. Resolution of this issue may only come with new
technologies or indeed the outcome of the planned trial
and it is possible that OPCs will have clinically beneficial
effects on the course of SCI independent of remyelination
by providing trophic support in the injured spine.
Whole-body models have been promising, although
extrapolation of rodent data to complicated human injury
is questionable and history warns caution in this regard.
There are numerous safety and purity issues regarding the
culture mechanisms and potential tumorigenic nature of
OPCs and any problems may lead to major setbacks for
the field. Finally whilst the investment and ethical climate
is currently favourable, turbulence in either of these facets
could hinder future treatments.
In summary, OPCs have the potential to treat SCI, but,
as discussed in this review, there are many hurdles to
overcome and numerous uncertainties. So far, animal stu-
dies have shown that any observable improvements are
modest and that OPC transplants are only successful in
acute lesions [44], so chronically injured patients or those
expecting miracles risk disappointment. Nonetheless, SCI
is a field in need of progress, exemplified by the fact that
many patients are so desperate for a cure that they are dri-
ven abroad for risky and expensive procedures [92-94].
Only time will tell if OPCs will treat SCI, but whilst they
have potential, there is at least hope for success.
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